Sareum Regulatory News (SAR)

Sareum Holdings plc

("Sareum" or the "Company")

Sareum to Present at BioTrinity 2022 Conference

Cambridge, UK, 26 April 2022 - Sareum Holdings plc (AIM: SAR), the specialist drug development company, announces that its CEO, Dr Tim Mitchell, will give a Company Showcase presentation at the BioTrinity 2022 conference, being held in London on 26 and 27 April.

In his presentation, Dr Mitchell will provide updates on the progress of Sareum's two proprietary TYK2/JAK1 kinase inhibitor programmes: SDC-1801, targeting autoimmune diseases and the severe inflammatory responses and respiratory symptoms arising from Covid-19 and other viral infections; and SDC-1802, targeting cancers.

A video copy of the presentation can be viewed by registered delegates throughout the BioTrinity event and will also be available on Sareum's website after the event: www.sareum.com. 

About BioTrinity

BioTrinity is an established, must-attend London conference that catalyses growth and supports in-person re-engagement across the life sciences industry.

The event is attended by an audience of early stage and emerging life sciences R&D companies, investors, big pharma, and other valued partners throughout the life sciences ecosystem. The conference features a focused, relevant, and stimulating programme, led by great speakers, who bring their knowledge, expertise, and vision to the fore in exciting, high-quality sessions.

For more information on the BioTrinity event, please visit www.biotrinity.com.

For further information, please contact: 

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the 'cytokine storm' immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com 

- Ends -